A major factor hindering the exploration of adoptive immunotherapy in preclinical settings is the limited availability of tumor-reactive human T cells. Here we developed a humanized mouse model that permits large-scale production of human T cells expressing the engineered melanoma antigen MART-1-specific TCR. 
INTRODUCTION
Infusion of in vitro expanded autologous tumorinfiltrating lymphocytes (TILs) following lymphodepletion has been shown to result in objective tumor regression in up to 70% of patients with metastatic melanoma, and almost a quarter of the treated patients achieved durable complete remission [1] . However, it is not always possible to obtain TILs with anti-melanoma activity and there has been limited success in obtaining TILs in other cancers. Thus, much effort has been devoted to develop efficient means of producing CTLs with antitumor activity. In addition, melanoma frequently relapses in the patients after a period of remission [1] , and the relapse was found to be associated with a tumor immunosuppressive microenvironment that inhibits T cell function [2] . Emerging evidence indicates that the tumor-induced inhibition of T cell activation is largely attributed to the recruitment of regulatory T cells (Tregs) into the tumor and upregulation of immune inhibitory pathway signaling, which are both driven by T cell immune responses [3, 4] . These studies imply that, for achieving the desired therapeutic effects of adoptive immunotherapy, it is important to develop effective approaches overcoming these immunosuppressive pathways. However, such studies have mostly been performed in mice, and the limited availability of tumor-reactive human CTLs that resemble those from patients is one of the key impeding factors.
It has been shown first in mice [5, 6] , and more recently in humans [7] that T cells expressing the transgenic TCR can be generated by introducing TCR genes into hematopoietic stem cells. We have previously shown that transplantation of human fetal thymus tissue (FTHY; under kidney capsule) and CD34
+ fetal liver cells (FLCs; i.v.) in immunodeficient mice leads to the development of human lymphohematopoietic cells including T, B and dendritic cells, and the formation of secondary lymphoid organs consisting of human lymphohematopoietic cells [8] [9] [10] . Here, we investigate the possibility of using this humanized mouse (hu-mouse) model to generate melanoma antigen (MART-1)-specific human T cells for translational studies of adoptive cancer immunotherapies. We show that MART-1-specific human T cells can be generated efficiently in hu-mice made of CD34 + FLCs that were transduced with lentiviruses containing MART-1-specific TCR gene. Importantly, MART-1-specific human T cells developed in hu-mice are functional and capable of killing melanoma cells in an HLA/peptide-dependent manner. Furthermore, using hu-mouse-derived melanoma antigen-specific human T cells, we demonstrate that pretreatment of the T cells with rapamycin can significantly enhance the antitumor activity of adoptive T cell therapy in IL-15-treatted recipients.
RESULTS

Development of melanoma antigen MART-1-specific human T cells in humanized mice made of TCR engineered CD34
+ cells
A lentiviral vector encoding HLA-A*0201-restricted TCR (DMF5 clone) [11] specific for melanoma-associated antigen recognized by T cell-1 (MART-1) was used Figure 1A ). We have shown that the use of cryopreservedthawed FTHY may improve T cell development from virally-transduced CD34
+ cells by eliminating preexisting T cell progenitors in the FTHY graft (Hu Z, Xia J, Yang YG. Unpublished data). In hu-mice that received HLA-A*0201 + FTHY and CD34 + FLCs transduced with lentiviral vectors containing MART-1-specific TCR gene, high levels of human T and B cell reconstitution were detected ( Figure S1 ) and among human CD3
+ T cells, a significant proportion was found to express MART-1-specific TCR, as identified by HLA-A2/MART-1 tetramer staining ( Figure 1B ). The majority of tetramer + T cells had a naïve phenotype as shown by expression of CD45RA and CCR7 ( Figure 1C Figure 1D and 1E). All mice had at least more than a million (ranging from 1.1x10 6 and 12x10 6 ) of tetramer + CD8 + T cells in the spleen, and a significant increase was seen in hu-mice receiving MART-1 peptide immunization (Table S1 ; also see Figure 2 below). Furthermore, most CD8 single positive (SP) and CD4
+
CD8
+ double positive (DP) thymocytes expressed MART-1-specific TCR ( Figure  1F ). Although the frequency was lower, peripheral human CD4 + T cells and CD4SP thymocytes also contained a significant proportion of tetramer + cells (with relatively lower levels of MART-1-TCR expression; Figure S2 ) in almost all mice examined ( Figure 1D-1F ).
Tetramer
+ CD8+, but not CD4
+
, T cells showed efficient in vivo responses following peptide immunization
Next we questioned if the tetramer + T cells generated in hu-mice were functional. We immunized the hu-mice with MART-1 peptides emulsified by complete Freud's adjuvant and measured the immune response 3 weeks later. Tetramer + CD8 + T cells showed a MART-1-specific response following immunization, as shown by antigen-specific expansion (Figure 2A ), conversion from a naïve to effector/memory phenotype (i.e., losing CCR7 and CD45RA expression; Figure 2B ), and IFN-γ production ( Figure 2C ). In contrast to tetramer + CD8 + T cells, tetramer -CD8 + T cells showed no detectable changes in either phenotypes or function after immunization with MART-1 peptides. However, unlike CD8 + T cells, neither tetramer + nor tetramer -CD4 + T cells showed expansion ( Figure 2D ), conversion to an effector/memory phenotype ( Figure 2E ) or IFN-γ production ( Figure 2F ) following MART-1 peptide immunization, despite that the tetramer +
CD4
+ T cells showed significant proliferation after in vitro stimulation with MART-1 peptides ( Figure S3 MART-1-specific human T cells developed in humanized mice induce efficient killing of melanoma cells in an antigen-specific manner, and retain their antigen-specific cytotoxicity after extensive in vitro expansion
We then measured the killing of melanoma cells by tetramer + T cells isolated from hu-mice. Tetramer + human T cells purified from hu-mice were stimulated for 5 days with anti-huCD3/CD28 microbeads, and their cytotoxicity against melanoma cells was assessed by 51 Cr-release assay. As shown in Figure 3A Figure S4 ). However, perforin production was not induced in tetramer + CD8 + T cells after stimulation with either Mel 624 or Mel 888 cells ( Figure S4 ), suggesting that perforin is not a major effector molecule for these T cells. Although to a markedly lower extend compared to tetramer + CD8 + T cells, tetramer + CD4 + T cells were also capable of mediating specific cytotoxicity and producing IFN-γ when cocultured with Mel 624, but not Mel 888, melanoma cells ( Figure 3D ). Taken together, these data demonstrate that tetramer + human T cells (especially CD8 
CCR7
-effector memory T cells. C. and F. Percentages of IFN-γ producing tetramer + CD8 + C. and CD4 + F. T cells prepared before and after immunization (mean ± SEMs; n = 5). *, p < 0.05; **, p < 0.01; ***, p < 0.001; n.s., not significant.
T cells) that developed in hu-mice are capable of killing melanoma cells in an HLA-A2/MART-1 peptide complexdependent manner. Furthermore, these tetramer + T cells can be substantially expanded in vitro without significantly compromising their cytotoxic activity.
Adoptive immunotherapy using in vitro-expanded MART-1-specific T cells generated in humanized mice
Tetramer + CD8 + T cells were sorted out from humouse splenocytes and expanded in vitro for approximately 30 days (Figure 4A ). At the end of expansion, the majority Figure 4C ). We then assessed the antitumor activity of the expanded MART-1-specific CD8 T cells in melanoma-bearing mice. In NSG mice that were subcutaneously inoculated with Mel 624 melanoma cells (1x10 6 per mouse), tumor growth was significantly inhibited by adoptive transfer of in vitro expanded tetramer + CD8 + T cells ( Figure 4D , left panel). Flow cytometric analysis revealed that most TILs were tetramer + CD8 + T cells with a CD45RA -CCR7 -effector/ memory phenotype ( Figure 4D, right panel) . Figure 4E ). These data provide direct in vivo evidence that tetramer + CD8 + T cells developed in hu-mice are capable of infiltrating into tumors and killing tumor cells after adoptive transfer into tumor-bearing recipients.
IL-15 promotes survival and antitumor responses of in vitro expanded MART-1 TCR + T cells
We then assessed the effect of IL-15 on the survival and antitumor activity of adoptively transferred tetramer 
cells with rapamycin immediately prior to adoptive therapy leads to markedly improved protection against metastatic melanoma
We further explore the potential of treatment with rapamycin prior to adoptive transfer to improve the survival and antitumor activity of tumor antigenspecific T cells. In vitro expanded tetramer + CD8 + T cells were cultured with rapamycin (100nM) for 3 days immediately before transfer into IL-15-treated or nontreated melanoma-bearing recipients that were injected i.v. with Mel 624 melanoma cells (1x10 5 per mouse). A short treatment with rapamycin significantly improved T cell survival in both non-treated and IL-15-treated recipients ( Figure 6A ). In the recipients without IL-15 treatment, the percentage of rapamycin-treated tetramer + CD8 + T (Rapa-T) cells measured at week 1 (0.86±0.09%) was significantly (approximately 3 fold) greater than that of non-treated tetramer + T (Ctrl-T) cells (0.30±0.06%; Figure  6A ). Treatment of the recipients with IL-15 synergistically enhanced the effect of rapamycin in improving T cell survival. The percentage of surviving Rapa-T cells at week 1 in IL-15-treated mice (Rapa-T/IL-15; 3.26±0.46%) was more than 10-fold and about 4-fold greater than that of Ctrl-T and Rapa-T cells, respectively, in mice that did not receive IL-15 treatment, and approximately 4-fold greater than that of Ctrl-T cells in IL-15-treated mice (Ctrl-T/IL-15; 0.84±0.14%; Figure 6A ).
Rapa-T cells also mediated significantly stronger antitumor responses than Ctrl-T cells. Consistent with the results shown in Figure 5B , adoptive transfer of Ctrl-T cells induced significant protection against metastatic melanoma, which was further enhanced by IL-15 treatment ( Figure 6B ). Compared to Ctrl-T cells, Rapa-T cells were significantly more effective in eradicating melanoma, leading to improved survival rates in mice with metastatic 5 Mel 624 cells only (Mel; n = 4). **, p < 0.01; ***, p < 0.001; n.s., not significant melanoma ( Figure 6B) . Notably, a powerful antitumor response leading to 100% survival for more than 300 days was seen in IL-15-treated mice infused with Rapa-T cells, while most of the mice receiving Rapa-T cells without IL-15 and half of the IL-15-treated mice receiving Ctrl-T cells succumbed to metastatic melanoma. All surviving mice were sacrificed at day 320 post-infusion and none showed detectable tumors at autopsy.
DISCUSSION
In this study, we developed a hu-mouse model that permits efficient generation of tumor antigen-specific human T cells from genetically engineered CD34 + cells. Using this model in combination with in vitro cell expansion, we were able to produce large quantities of melanoma antigen MART-1-specific T cells with antigenspecific antitumor activity. This approach provides a practical means of producing potentially unlimited source of tumor-specific human T cells, which can be used in the development and testing of new cancer immunotherapy protocols in the preclinical settings. The recent development of "personalized immune (PI)" humice demonstrates the feasibility of generating patientspecific human T cells [13] . Thus, the combination of the strategy described in the current study with the "PI" humouse model may permit the production of tumor-reactive human T cells for preclinical exploration of individualized cancer immunotherapy.
Clinical trials using autologous peripheral lymphocytes genetically engineered by retroviral vector containing tumor antigen specific TCR gene have shown objective cancer regression in 10-30% patients with metastatic melanoma [14] [15] [16] . However, a challenge for this strategy is to prevent misparing of the endogenous TCR subunits with introduced TCR chains in the genetically-manipulated T cells, which may potentially alter TCR specificity leading to not only the loss of antitumor responses, but also formation of autoreactive T cells [17] [18] [19] . Unlike genetically engineered mature T cells, MART-1-TCR + human T cells in the hu-mouse are developed from TCR gene-transduced hematopoietic stem cells, so that most of these cells should express only the tumor antigen-specific TCR.
As expected, the majority of human T cells expressing the HLA-A2-restricted MART-1-TCR + developing in hu-mice expressed CD8. However, these humice also had a significant population of tetramer + CD4 +
T cells including FoxP3
+ CD4 + Tregs ( Figure S5 ). Similar to our results, the presence of CD4 + [20] and CD4 -
CD8
- [21] human T cells that recognize melanoma antigens in an HLA class I-restricted manner was also found in humans. Previous studies on the ability of MHC class I-restricted CD4 T cells to generate antitumor effects have been contradictory [22] [23] [24] [25] . A recent study showed that the antitumor efficacy of CD4 + T cells expressing MHC class I-restricted TCR depends on TCR affinity, and only those with high affinity TCR may mediate CD8-independent cytotoxicity [26] . In the present study, we showed that, although to a significantly lower extent than tetramer + CD8 + T cells, tetramer + CD4 + T cells developing in the hu-mice were also functional and capable of mediating antigen-specific responses (i.e., cytotoxicity and IFN-γ production) in vitro when cocultured with the target cells. However, we failed to detect antigen-specific responses in tetramer + CD4 + T cells from MART-1 peptide-immunized hu-mice, despite that tetramer + CD8 + T cells from the same hu-mice responded robustly to immunization. Clearly, further studies are needed to determine whether the tetramer + CD4 + T cells may provide help to CD8 T cells expressing the same TCR. Nonetheless, our results implicate that in vitro analysis may not accurately predicate the in vivo antitumor effect of tumor antigensspecific T cells.
IL-15 is an immune regulatory cytokine with broad activities that include inducing differentiation and proliferation of T, B and NK cells, enhancing the cytolytic activity of CD8 + T cells and contributing to long term survival of memory T cells [27] . The potential of IL-15 to promote the survival and antitumor activity of adoptively transferred tumor-specific CD8
+ T cells has been demonstrated in mice [28, 29] , but remains poorly understood in humans. In the present study, we observed that in vivo treatment with IL-15 dramatically promoted the survival and/or proliferation of activated MART-1-TCR + CD8 T cells, which was associated with a significantly increased antitumor effect, in melanomabearing hosts. The data support the idea of using IL-15 to enhance antitumor responses of adoptive T-cell transfer therapy, and a clinical trial launched recently to test the effectiveness of TIL administration combined with IL-15 in metastatic melanoma [27] .
Another novel observation made in this study is that IL-15 administration combined with infusion of rapamycin-treated MART-1-TCR + human CD8 + T cells produced a strong synergistic effect in promoting the survival and antitumor responses of adoptively transferred tumor antigen-specific human T cells. It has been shown that inhibition of mTORC1 by rapamycin promotes memory CD8
+ T cell generation and function [30, 31] through down-regulation of T-bet and upregulation of Eomes in CD8 + T cells [32] . Using TCR transgenic mouse models, it was recently reported that a short course of injection with rapamycin enhances vaccine-induced CD8 + T cell memory and antitumor responses in mice [33, 34] . In this study, we observed that a brief culture of human CD8 + T cells with rapamycin significantly improved their survival and antitumor responses in melanomabearing recipients, particularly in mice treated IL-15.
Since enhanced CD8
+ T cell memory responses by mTOR inhibition is independent of IL-15 [32, 33] , rapamycintreated CD8 T cells should retain the ability to respond to the survival signaling provided by IL-15, which may explain why IL-15 and rapamycin can act synergistically to improve the survival and antitumor responses of tumor antigen-specific CD8 + T cells. The combinatorial treatment of the tumor-reactive CD8 T cells with rapamycin and of the recipient with IL-15 may provide a novel protocol for potentiating adoptive T cell immunotherapy.
MATERIALS AND METHODS
Animals and human tissues and cells
NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NOD/SCID/c -/-or NSG) mice were purchased from the Jackson Laboratory (Bar Harbor, ME), housed in a specific pathogen-free micro-isolator environment and used in experiments at 6 to 8 weeks of age. Human fetal thymus and liver tissues of gestational age of 17 to 20 weeks were obtained from Advanced Bioscience Resource (Alameda, CA). Protocols involving the use of discarded human tissues and animals were approved by the Institutional Review Board (IRB) and Institutional Animal Care and Use Committee (IACUC) of Columbia University Medical Center (New York, NY).
Humanized mouse preparation
NSG mice were conditioned with sublethal (2 Gy) total body irradiation, and received lentiviral vector transduced human CD34 + FLCs (2×10 5 /mouse, i.v.) with a cryopreservation treated FTHY fragment measuring about 1mm 3 (under the recipient kidney capsule) from the same fetal donor, as previously described [9, 10] . CD34 + FLCs were isolated by a magnetic-activated cell sorter (MACS) separation system using anti-CD34 microbeads (Miltenyi Biotec, Auburn, CA). Levels of human hematopoietic cells in humanized mice were determined by flow cytometric (FCM) analysis using various combinations of the following mAbs: anti-human CD45, CD19, CD3, CD4, CD8, CD45RA, CCR7; anti-mouse CD45 and Ter119; and isotype control mAbs (all antibodies were purchased from BD PharMingen, San Diego, CA).
MART-1-TCR
+ T cells were identified by HLA-A*0201/ MART-1 (ELAGIGILTV) Tetramer (Beckman Coulter Immunotech). Mononuclear cells were prepared using density gradient centrifugation with Histopaque 1077 (Sigma-Aldrich, St. Louis, MO). Analysis was performed on a FACSCanto or LSR II (Becton Dickinson, Mountain View, CA). Dead cells were excluded from the analysis by gating out lower forward scatter and high propidium iodide-retaining cells.
Lentiviral production and human CD34 + FLC transduction
Pseudotyped lentiviral vectors were produced by transfection using Lipofectamine 2000 (Invitrogen, San Diego, CA) of 293FT cells in 10-cm plates. a 4-plasmid system consisting of the transfer vector (MART-1 antigen specific TCR, DMF5 clone; 10µg) and 3 packaging plasmids (VSV-G 3.6µg, pMDLg/pRRE 6.7 µg, and pRSV-Rev 6.7 µg) was used for MART-1 TCR-lentivirus production. The supernatant was collected 48 hour posttransfection and concentrated by ultracentrifugation at 50,000 g for 2 hours. Lentiviruses were stored at -80°C until use. Human CD34 + FLCs were stimulated overnight in media containing 50ng/mL rhSCF (R&D, Minneapolis, MN), 50ng/mL Flt3L (ebioscience, San Diego, CA), 25 ng/mL TPO (R&D), and 10ng/mL IL-3 (R&D), in a 24-well plate pre-coated with retronectin (Takara Bio Inc), followed by transduction with lentiviral vectors for 12 hours. Cells were washed twice and intravenously injected into sub-lethal irradiated mice as described above.
MART-1 peptide immunization
MART-1 peptides (ELAGIGILTV, Biosynthesis Inc, Lewisville, Texas) were emulsified with Freud's Complete Adjuvant (CFA) with 1:1 ratio and subcutaneously injected into humanized mice. Immunized mice were analyzed for MART-1-specific responses 3 weeks after immunization.
CTL assay
Purified MART-1 tetramer + human T cells were co-incubated with 51 Cr-labeled melanoma cells at the indicated effector:target (E:T) ratios in 96-well plates at 37°C for 4-6 hours. Lysis of tumor cells was measured by 51 Cr release in the supernatant counted using a Perkin 
In vitro expansion of MART-1 antigen specific T cells
MART-1 tetramer
+ T cells were purified from lymphoid organs of humanized mice by cell sorting using an Influx cell sorter (BD Biosciences) and expanded in vitro using a previously described protocol with some modification [35, 36] . Briefly, purified T cells were stimulated with pooled allogeneic PBMCs (1.5×10 7 /mL, 35 Gy irradiated) and Epstein-Barr virus-transformed lymphoblastoid cell lines (EBV-LCL, 4.3×10 5 /mL, 60 Gy irradiated), 30 ng/mL anti-huCD3 (OKT3), and 100U/ mL recombinant human IL-2 (rhIL-2) in RMPI 1640 medium supplemented with 10% human AB serum. One third of the culture supernatant was replaced with fresh media containing 300U/mL rhIL-2 every 2-3 days. The cells were restimulated with anti-human CD3 and freshly irradiated feeder cells (i.e., allogeneic PBMCs and EBV-LCL) every 2 weeks.
Assessment of antitumor effects of in vitroexpanded MART-1 TCR + T cells in melanomabearing mice
In vitro expanded CD8 MART-1 TCR + T cells were adoptively transferred (i.v.) into NSG mice that were inoculated with Mel 624 cells (s.c. or i.v.) on the same day, and the antitumor effect was evaluated by measuring tumor mass or recipient survival time in mice receiving s.c. and i.v. injection of melanoma cells, respectively. Tumor mass was measured using fine calipers (Marathon, Richmond Hill, Canada) and calculated by the product of the two largest perpendicular diameters a×b (mm 2 ), as previously described [6] . To assess the effect of IL-15 on antitumor responses, some recipient mice were given hydrodynamic injection (50μg/2mL/mouse via tail vein) of plasmid containing rhIL-15 gene one day prior to injection of melanoma cells, as previously described [12] . In some experiments, rapamycin (100nM; Sigma Aldrich; St. Louis, Missouri) was added into the T cell expansion culture for 3 days immediately before adoptive transfer.
Statistical analysis
The level of significant differences in group means was determined by the student's t test. Graft survival data were presented as Kaplan-Meier survival curves and differences between groups were analyzed by logrank test using GraphPad Prism (San Diego, CA). All statistical analysis was performed using Prism 4 (GraphPad Software, San Diego, CA). A p value of ≤ .05 was considered significant in all analyses herein.
